Stratec Se (SBS.DE) Osake Kurssi
Stratec Se Kurssi
Liikevaihto on kasvanut 7,6 % vuodessa viimeisten 18 vuoden aikana 250,86 M EUR:een. Osakekohtainen tulos on kasvanut 5,8 % vuodessa viimeisten 16 vuoden aikana. Stratec Sen nettomarginaali on nyt −0,1 %, laskenut 13,9 %:sta muutama vuosi sitten. Stratec Sen osinkotuotto on tällä hetkellä noin 2,78 %. Osinko on kasvanut 9,9 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 31,11 EUR, eli yli nykyhintaa 44,4 %. 11 analyytikosta 8 suosittaa ostoa — kokonaiskonsensus on Osta.
Stratec Se osakekurssi
Stratec Se liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Stratec Se -osakkeesta
The business model of Stratec SE revolves around providing innovative solutions and services to the diagnostics industry. As a leading global technology partner, Stratec SE specializes in developing and producing automated analyzer systems that enable fast, reliable, and cost-effective diagnostics. By focusing on instrument and assay integration, Stratec SE helps its customers streamline their processes and improve laboratory efficiency. The company's comprehensive portfolio covers a wide range of applications, including clinical diagnostics, blood banking, and pharmaceutical quality control. With its expertise and cutting-edge technologies, Stratec SE aims to drive advancements in diagnostics and contribute to improving patient care worldwide.
Stratec SE is primarily active in the life sciences and medical technology industries.
The main competitors of Stratec SE in the market include companies like Thermo Fisher Scientific, Becton, Dickinson and Company, PerkinElmer Inc., and Bio-Rad Laboratories.
Stratec SE, a leading global supplier of laboratory automation and diagnostic solutions, has a rich history and background. Established in 1979 in Birkenfeld, Germany, the company has grown from a small start-up to a renowned player in the life science industry. Stratec SE specializes in developing innovative technologies and devices that enable faster and more efficient diagnostics and research processes. With a strong focus on customer satisfaction and strategic partnerships, Stratec SE has expanded its presence worldwide. Today, the company serves a diverse range of customers, including pharmaceutical firms, medical device manufacturers, and research institutions. Stratec SE's dedication to technological advancement and commitment to quality make it a trusted name in the industry.
Stratec SE, a renowned stock company, has accomplished several notable milestones throughout its journey. One prominent achievement is the successful development of innovative laboratory and diagnostic solutions for the global healthcare industry. Stratec SE has also gained recognition for its strategic partnerships and collaborations, fostering growth and expanding its market presence. Moreover, the company has consistently delivered strong financial performance, achieving sustainable revenue growth and enhancing shareholder value. Stratec SE's commitment to continuous innovation, dedication to quality, and focus on customer satisfaction has positioned it as a key player in the industry, ensuring its ongoing success and reputation as a trusted stock investment.
Stratec SE is primarily present in various countries and regions. As a global company, its presence extends across Europe, North America, and Asia. Stratec SE operates in countries such as Germany, Switzerland, the United States, China, and Japan, among others. With its strong international footprint, Stratec SE has established itself as a leading provider of innovative solutions in the fields of in-vitro diagnostics and life sciences.
Stratec SE represents a strong set of values and corporate philosophy. With a focus on innovation and quality, the company aims to provide cutting-edge solutions in the field of automation and instrumentation for medical diagnostics. Stratec SE puts a strong emphasis on customer satisfaction and long-term partnerships, striving for continuous improvement and excellence. By fostering a culture of collaboration, integrity, and professionalism, the company aims to drive sustainable growth and deliver value to its shareholders. Stratec SE's commitment to delivering high-performance products and services, coupled with its dedication to corporate responsibility, sets it apart in the industry.
Analyytikot asettavat tällä hetkellä Stratec Se-osakkeelle keskimääräisen tavoitehinnan 34,95 EUR (mediaani: 31,11 EUR), mikä merkitsee +62,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.
11 analyytikkoa arvioi tällä hetkellä Stratec Se-osaketta: 8 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Stratec Se-yhtiöltä 267,02 M EUR liikevaihtoa ja 1,45 EUR osakekohtaista tulosta.
Stratec Se-osake (SBS.DE) on listattuna 8 pörssissä, muun muassa: London (0RAR.L), SIX (Zürich) (SBS.SW), XETRA (SBS.DE), Frankfurt (SBS.F), München (SBS.MU), Düsseldorf (SBS.DU), Hamburg (SBS.HM).
Stratec SE is a leading provider of automation solutions for the diagnostic and analytic industry. The company offers a wide portfolio of products and services that are part of its core business. Stratec operates in two business segments: instrumentation and diagnostics. (Instrumentation) Stratec offers a wide range of automation solutions, including the development, production, and distribution of equipment and systems for automated sample processing in clinical laboratories, as well as industrial automation for the production of medical devices and system solutions in the fields of life science and diagnostics. The company is a market leader in immunology and hematology and is also present in other segments such as microbiology and molecular biology. (Diagnostics) The diagnostic business segment provides specialized immunological and molecular tests for a variety of medical applications in the in vitro diagnostic (IVD) market. The company focuses on immuno-oncology, gastroenterology, infectious diseases, and cardiovascular diseases. Stratec offers comprehensive development, production, quality control, life cycle, and market release management services. The company emphasizes close collaboration with its customers to develop innovative solutions of the highest quality that meet the highest requirements for precision, reliability, and scalability. Stratec has demonstrated its resilience, successfully navigating through the COVID-19 pandemic in 2020. The company has proven to be crisis-resistant and has guided its employees through the crisis. With a strong global presence and industry-specific expertise, Stratec is able to continuously meet customer requirements. The company has established its business in the United Kingdom and the United States and plans to expand into other countries, primarily in Asia. Wherever Stratec operates, it emphasizes open and collaborative partnerships with customers and other stakeholders. Overall, Stratec SE is a company that impresses with its comprehensive automation solutions for the diagnostic and analytic industry. The instrumentation business segment covers multiple areas of medicine, while the diagnostics business segment specializes in the development and production of diagnostic solutions. Together, both segments enable optimal collaboration with customers and comprehensive expertise in the industry. The company is capable of addressing both customer needs and industry requirements as a whole.
odotettu liikevaihto Stratec Se on 267,02 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Stratec Se on 17,63 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Stratec Se:n hinta-voitto-suhde (P/E) on tällä hetkellä 14,86. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Stratec Se-osakkeen arvostusta.
Stratec Se:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,98. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Stratec Se-osakkeen arvostuskennuslukuna.
Stratec Se:n Eulpool-laatuscore on 1/10.
Stratec Se:n ISIN on DE000STRA555. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Stratec Se:n WKN on STRA55. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Stratec Se:n ticker on SBS.DE. Tämä pörssinoteeraus käytetään Stratec Se-osakkeiden kauppaan pörssissä.
Stratec Se osake
Stratec Se vertaisryhmä
Stratec Se Ticker
Stratec Se FIGI
Kaikki tunnusluvut ja syvällinen analyysi Stratec Se:sta
Meidän osakeanalyysimme Stratec Se-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Stratec Se:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: